Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure

Laboratory Investigation

Volumn 78, Issue 7, 1998, Pages 813-824

  Schelling, Jeffrey R ^a,b   Nkemere, Nnenna ^a,b   Kopp, Jeffrey B ^c   Cleveland, Ronald P ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; KIDNEY CORTEX; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL DIVISION; CELL LINE, TRANSFORMED; EPITHELIAL CELLS; FLOW CYTOMETRY; GENES, P53; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; PROLIFERATING CELL NUCLEAR ANTIGEN; REFERENCE VALUES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031850058     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, and Cerretti DP (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729-733.
2. Bohle A, Mackensen-Haen S, and von Gise H (1988). Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: A morphometric contribution. Am J Nephrol 7:421-433.
3. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y, Camonis JH, and Wallach D (1995). Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 270:387-391.
4. Boonstra JG, Van der Woude FJ, Wever PC, Laterveer JC, Daha MR, and Van Kooten C (1997). Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol 8:1517-1524.
5. Bódi I, Abraham AA, and Kimmel PL (1995). Apoptosis in human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 26:286-291.
6. Brady HR (1995). Leukocyte adhesion molecules. In: Schlondorff D and Bonventre JV, editors. Molecular nephrology: Kidney function in health and disease. New York: Dekker, 717-740.
7. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, and Barr PJ (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762.
8. Chomczynski P and Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 162:156-159.
9. Cleveland RP and Liu YC (1996). CD4 Expression by erythroid precursor cells in human bone marrow. Blood 87: 2275-2282.
10. Colucci WS (1996). Apoptosis in the heart. N Engl J Med 335:1224-1226.
11. Dowling P, Shang GF, Raval S, Menonna J, Cook S, and Husar W (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184:1513-1518.
12. Eddy AA (1996). Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508.
13. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, and Runkel L (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223-1230.
14. Gavrieli Y, Sherman Y, and Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501.
15. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, and Galluzzo A (1997). Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275:960-963.
16. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, and Varmus HE (1996). Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev 10:836-850.
17. Haverty TP, Kelly CJ, Hines WH, Amenta PS, Watanabe M, Harper RA, Kefalides NA, and Neilson EG (1988). Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J Cell Biol 107:1359-1368.
18. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, and Brenner BM (1981). Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-93.
19. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Seto Y, and Nagata S (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243.
20. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, and Yagita H (1995). Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783.
21. Kelley VE and Roths JB (1985). Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 37:220-229.
22. Kondo T, Suda T, Fukuyama H, Adachi M, and Nagata S (1997). Essential roles of the Fas ligand in the development of hepatitis. Nat Med 4:409-413.
23. Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, and Atkins RC (1995). Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 47:1303-1309.
24. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Schmidt A, Debatin KM, Krammer PH, and Moller P (1993). Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429.
25. Maciejewski J, Selleri C, Anderson S, and Young NS (1995). Fas antigen expression on CD34+ human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:3183-3190.
26. Majno G and Joris I (1995). Apoptosis, oncosis, and necrosis: An overview of cell death. Am J Pathol 146:3-15.
27. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, and Fontaine G (1996). Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med 335:1190-1196.
28. Mariani SM, Matiba B, Bäumler C, and Krammer PH (1995). Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 25:2303-2307.
29. Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, and Warner J (1997). Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733-736.
30. Nadasdy T, Laszik Z, Blick KE, Johnson DL, and Silva FG (1994). Tubular atrophy in the end-stage kidney: A lectin and immunohistochemical study. Hum Pathol 25:22-28.
31. Nagata S (1997). Apoptosis by death factor. Cell 88:355-365.
32. Nath KA (1992). Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20:1-17.
33. O'Connell J, O'Sullivan GC, Collins JK, and Shanahan F (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082.
34. Ortiz-Arduan A, Danoff TM, Kalluri R, Gonzalez-Cuadrado S, Karp SL, Elkon K, Egido J, and Neilson EG (1996). Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 271:F1193-F1201.
35. Racusen LC, Monteil C, Sgrignoli A, Lucskay M, Marouillat S, Rhim JG, and Morin JP (1997). Cell lines with extended in vitro growth potential form human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 129:318-329.
36. Risdon RA, Sloper JC, and De Wardener HE (1968). Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363-366.
37. Schainuck LI, Striker GE, Cutler RE, and Benditt EP (1970). Structural-functional correlations in renal disease. Hum Pathol 1:631-641.
38. Schelling JR, Gentry DJ, and Dubyak GR (1996). Annexin II inhibition of G protein-regulated inositol triphosphate formation in rat aortic smooth muscle. Am J Physiol 270:F682-F690.
39. Schelling JR, Nkemere N, Konieczkowski M, Martin KA, and Dubyak GR (1997). Angiotensin II activates the β1 isoform of phospholipase C in vascular smooth muscle cells. Am J Physiol 272:C1558-C1566.
40. Schumer M, Colombel MC, Sawczuk IS, Gobe G, Connor J, O'Toole KM, Olsson CA, Wise GJ, and Buttyan R (1992). Morphologic, biochemical, and molecular evidence of apoptosis during reperfusion phase after brief periods of renal ischemia. Am J Pathol 140:831-838.
41. Sedor JR (1994). Cytokines, kidney disease, and therapy: A molecular characterization provides insights into mechanism. J Lab Clin Med 124:470-472.
42. Suda T, Takahashi T, Golstein P, and Nagata S (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178.
43. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, and Ota Z (1996). Apoptosis in glomerular sclerosis. Kidney Int 49:103-111.
44. Takemura T, Murakami K, Miyazato H, Yagi K, and Yoshioka K (1995). Expression of Fas antigen and Bcl-2 in human glomerulonephritis. Kidney Int 48:1886-1892.
45. Tanaka M, Itai T, Adachi M, and Ngata S (1998). Downregulation of Fas ligand by shedding. Nat Med 4:31-36.
46. Tanaka M, Suda T, Takahashi T, and Nagata S (1995). Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14:1129-1135.
47. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, and Nagata S (1992a). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317.
48. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, and Nagata S (1992b). The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148:1274-1279.
49. Woo D (1995). Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333:18-25.
50. Yamamoto T and Wilson CB (1987). Complement dependence of antibody-induced mesangial cell injury in the rat. J Immunol 138:3758-3765.
51. Yoshioka K, Takemura T, Murakami K, Okada M, Yagi K, Miyazato H, and Maki S (1993). In situ expression of cytokines in IgA nephritis. Kidney Int 44:825-833.
52. Zalups RK (1993). The Os/+ mouse: A genetic animal model of reduced renal mass. Am J Physiol 264:F53-F60.
53. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, and Brenner BM (1986). Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930.